Time to stop worrying about <scp>ABO</scp> incompatible cryoprecipitate transfusions in adults

Khan, Jenna; Dunbar, Nancy M.

doi:10.1111/trf.16228

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports have illustrated transfusing ABO‐incompatible plasma can result in clinical and laboratory evidence of haemolysis [21]. Given the presence of residual plasma in cryoprecipitate units, concern for haemolysis has been attributed to the transfusion of ABO‐incompatible cryoprecipitate.…”

Section: Discussionmentioning

confidence: 99%

Practice patterns of ABO‐matching for cryoprecipitate and patient outcomes after ABO‐compatible versus incompatible cryoprecipitate

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: This sub-study of the FIBRES trial sought to examine the patterns of ABO-compatible cryoprecipitate administration and to identify adverse consequences of ABO-incompatible cryoprecipitate. Materials and Methods:This was a post hoc analysis of data collected from the FIBRES randomized clinical trial comparing fibrinogen concentrate with cryoprecipitate in the treatment of bleeding related to hypofibrinogenemia after cardiac surgery.The primary outcome was the percentage of administered cryoprecipitate that was ABO-compatible. Secondary outcomes were adverse events at 28 days. A follow-up survey was distributed to the FIBRES participating sites to examine the rationale behind the identified cryoprecipitate ABO-matching practice patterns.Results: A total of 363 patients were included: 53 (15%) received ABO-incompatible cryoprecipitate and 310 (85%) received ABO-compatible cryoprecipitate. There was an increased incidence of post-operative anaemia in the ABO-incompatible group (15; 28.3%) in comparison to the ABO-compatible (44; 14.2%) group (p = 0.01) at 28 days, which was unrelated to haemolysis, without a significant difference in transfusion requirement. In the multivariable logistic regression models accounting for clustering by site, there was no observed statistically significant association between the administration of ABO-incompatible cryoprecipitate and any other adverse outcomes. Nine out of 11 sites did not have a policy requiring ABO-matched cryoprecipitate. Conclusion:This sub-study demonstrated that most cryoprecipitate administered in practice is ABO-compatible, despite the absence of guidelines or blood bank policies to support this practice. A signal towards increased risk of post-operative anaemia may be explained by higher rates of urgent surgery (vs. elective) in the ABOincompatible group. Future studies should prospectively examine the impact of ABO-compatible versus incompatible cryoprecipitate to conclusively establish if there is a meaningful clinical impact associated with the administration of ABOincompatible cryoprecipitate.

show abstract

Section: Discussionmentioning

confidence: 99%

Practice patterns of ABO‐matching for cryoprecipitate and patient outcomes after ABO‐compatible versus incompatible cryoprecipitate

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Also, COVID-19 leads to protracted symptoms in a subset of sufferers [ 19 ], preventing them from blood donation for several months. Data from COVID-19 convalescent donors of plasma indicate that reduced hemoglobin levels compared to pre-infection values are a general feature of COVID-19 [Nissen-Meyer et al, unpublished] and this was a major source of donor deferral in a study from New York [ 20 ]. Additionally, the antibody screening will fail to identify donors with a weak antibody response or whose antibody levels over time have decreased below the detection limit.…”

Section: Discussionmentioning

confidence: 99%

Sero-prevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Norway, winter/spring 2021

Hvalryg

Nissen‐Meyer

2021

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Cross-sectional studies of the prevalence of anti-SARS-CoV-2 in representative groups are routinely used for surveillance of public health in Norway. The group of blood donors is easily accessible to provide an estimate over the infection prevalence. Repeated testing of returning donors also generates data about the duration of the antibody response following infection and vaccination. The aim of the current study was to provide updated information about the development of the pandemic in the blood donor population, and to estimate the number of asymptomatic donors visiting the blood center, in an effort to evaluate the measures to prevent virus spreading between donors and staff. In the two main blood banks in the Oslo area, all blood donors were offered antibody testing for a period of three months. Almost 12,000 donors were tested, and the mean weekly prevalence of antibody positive donors due to infection was 2.7 % (varied from 2.1 to 4.0 %). The number of donors presenting following vaccination was 810 (6.9 %). An average of 38 % of the infections had been asymptomatic, and 31 % of the antibody-positive donors were unaware of having been infected. In conclusion, the proportion of blood donors seropositive for anti-SARS-CoV-2 in our blood centers was stable whereas the number of vaccinated blood donors rapidly increased. This indicates that the virus spreading in the third wave of infection in the Oslo area mainly happened in groups underrepresented as blood donors. Health care workers prioritized for early vaccination may be overrepresented in the study period.

show abstract

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Rosa-Nunes,

Lucchi,

Andreata-Santos

et al. 2023

Front. Drug Discov.

View full text Add to dashboard Cite

In the 21st Century, emergence and re-emergence of infectious diseases is significant and has an increasing importance in global concern of public health. Based on the COVID-19 pandemic and recently reported epidemics, most human pathogens originate in zoonosis. Many of such pathogens are related to viruses that have RNA genomes, which can be presented structurally as a single-strand or double-strand. During the last two decades, a timeline of major RNA viruses emergencies can be exemplified, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003, influenza A virus (H1N1) pdm09 in 2009, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola virus (EBOV) in 2013–2016, Zika virus (ZIKV) in 2015 and the SARS-CoV-2 pdm19 in 2019. Even so, prophylactic or therapeutic drugs are unavailable for many RNA viruses circulating. Nonetheless, the COVID-19 pandemic brought considerable scientific advances in accelerating progress regarding prophylaxis, antiviral and drug development, and novel treatments. Regarding RNA virus diseases for humans, arboviruses play an essential and neglected role, constantly reemerging and affecting almost half of the human population, for which no drug has been licensed. Here we review the consolidated RNA viruses’ emergence and re-emergence in the 21st Century through available data. Then, we explored valuable lessons gained during the SARS-CoV-2 pandemic and focused on potential epidemiologic updates, prophylaxis, available treatments, and viral drug inhibitors. Finally, we explore arbovirus’s significance and the ongoing development of effective vaccines, antiviral drugs, and novel therapeutic approaches as strategies to control these neglected tropical diseases (NTD).

show abstract

Time to stop worrying about ABO incompatible cryoprecipitate transfusions in adults

Cited by 3 publications

References 25 publications

Practice patterns of ABO‐matching for cryoprecipitate and patient outcomes after ABO‐compatible versus incompatible cryoprecipitate

Practice patterns of ABO‐matching for cryoprecipitate and patient outcomes after ABO‐compatible versus incompatible cryoprecipitate

Sero-prevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Norway, winter/spring 2021

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Contact Info

Product

Resources

About